Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation

American Journal of Gastroenterology

Volumn 106, Issue 12, 2011, Pages 2154-2164

  Wong, Banny S ^a   Camilleri, Michael ^a   McKinzie, Sanna ^a   Burton, Duane ^a   Graffner, Hans ^b   Zinsmeister, Alan R ^c  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Albireo   (Sweden)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7ALPHA HYDROXYCHOLEST 4 EN 3 ONE; A 3309; BILE ACID; GASTROINTESTINAL AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTICLE; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FECES ANALYSIS; FEMALE; HUMAN; INTESTINE TRANSIT TIME; MALABSORPTION; PRIORITY JOURNAL;

ADULT; CARRIER PROTEINS; CHOLESTENONES; COLIC; COLON; CONSTIPATION; DIARRHEA; DOUBLE-BLIND METHOD; FECES; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; HUMANS; LIPOPROTEINS, LDL; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; SYMPORTERS; TREATMENT OUTCOME;

EID: 82955195427     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.285     Document Type: Article

References (38)

1. Iser JH, Sali A. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use. Drugs 1981; 21: 90-119. (Pubitemid 12211943)
2. Mitchell WD, Findlay JM, Prescott RJ et al. Bile acids in the diarrhoea of ileal resection. Gut 1973; 14: 348-53.
3. Camilleri M, Murphy R, Chadwick VS. Dose-related effects of chenodeoxycholic acid in the rabbit colon. Dig Dis Sci 1980; 25: 433-8. (Pubitemid 10124424)
4. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest 1971; 50: 1569-77.
5. Conley DR, Coyne MJ, Bonorris GG et al. Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit. Am J Dig Dis 1976; 21: 453-8.
6. Chadwick VS, Gaginella TS, Carlson GL et al. Eff ect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med 1979; 94: 661-74. (Pubitemid 10210498)
7. Raimondi F, Santoro P, Barone MV et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol 2008; 294: G906-13. (Pubitemid 351520062)
8. Alrefai WA, Saksena S, Tyagi S et al. Taurodeoxycholate modulates apical Cl-/OH-exchange activity in Caco2 cells. Dig Dis Sci 2007; 52: 1270-8. (Pubitemid 46626156)
9. Bampton PA, Dinning PG, Kennedy y ML et al. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol 2002; 282: G443-9. (Pubitemid 34651659)
10. Kirwan WO, Smith AN, Mitchell WD et al. Bile acids and colonic motility in the rabbit and the human. Gut 1975; 16: 894-902.
11. Mok HY, Bell GD, Dowling RH. Eff ect of diff erent doses of chenodeoxycholic acid on bile-lipid composition and on frequency of side-effects in patients with gallstones. Lancet 1974; 2: 253-7.
12. Rao AS, Wong BS, Camilleri M et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549-58.
13. Gillberg PG, Dahlstr ö m M, Starke I et al. The IBAT inhibition by A3309-a potential mechanism for the treatment of constipation. Gastroenterology 2010; 5 (Suppl 1): 224.
14. Simren M, Bajor A, Gillberg P-G et al. Randomized clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation-a double-blind study. Aliment Pharmacol Th er 2011; 34: 41-50.
15. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl 2): II43-7. (Pubitemid 29434812)
16. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4. (Pubitemid 27382038)
17. Manabe N, Wong BS, Camilleri M et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22: 293-382.
18. Cremonini F, Mullan BP, Camilleri M et al. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002; 16: 1781-90.
19. Deiteren A, Camilleri M, Bharucha AE et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010; 22: 415-23.
20. Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 2010; 87: 748-53.
21. Chey WD, Camilleri M, Chang L et al. A randomized placebo-controlled phase Iib trial of A3309, a bile acid transporter inhibitor, for chronic idio pathic constipation. Am J Gastroenterol; published online, 24 May 2011 [E-pub ahead of print].
22. Rao S, Lembo A, Shiff SJ et al. Effi cacy and safety of once daily linaclotide in patients with irritable bowel syndrome with constipation: a 12-week, randomized, double-blind, placebo-controlled phase 3 trial followed by a 4-week randomized withdrawal period. Gastroenterology 2011; 140 (Suppl 1): S-138.
23. Andresen V, Camilleri M, Busciglio I et al. Eff ect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007; 133: 761-8. (Pubitemid 47374145)
24. Brydon WG, Nyhlin H, Eastwood MA et al. Serum 7 alpha-hydroxy-4- cholesten-3-one and seleno-homocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol 1996; 8: 117-23. (Pubitemid 26130232)
25. Gälman C, Arvidsson I, Angelin B et al. Monitoring hepatic cholesterol 7-hydroxylase activity by assay of the stable bile acid intermediate 7-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003; 44: 859-65. (Pubitemid 37279689)
26. Abrahamsson H, Ostlund-Lindqvist AM, Nilsson R et al. Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol 2008; 43: 1483-8.
27. Duane WC, Adler RD, Bennion LJ et al. Determination of bile acid pool size in man: a simplifi ed method with advantages of increases precision, shortened analysis time, and decreased isotope exposure. J Lipid Res 1975; 16: 155-8.
28. Odunsi ST, Camilleri M, McKinzie S et al. Eff ects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8: 159-65.
29. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386-90. (Pubitemid 40255465)
30. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-77.
31. Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab 2010; 299: E10-3.
32. Morvay K, Szentleleki K, Torok G et al. Eff ect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazineinduced colon cancer in rats. Dis Colon Rectum 1989; 32: 860-3. (Pubitemid 19255377)
33. Buchwald H, Varco RL, Boen JR et al. Eff ective lipid modifi cation by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: fi ve-year post-trial follow-up report from the POSCH: Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998; 158: 1253-61. (Pubitemid 28252490)
34. Buchwald H, Rudser KD, Williams SE et al. Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg 2010; 251: 1034-40.
35. Bajor A, Gillberg PG, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 2010; 45: 645-64.
36. Wong RK, Palsson OS, Turner MJ et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 2010; 105: 2228-34.
37. Camilleri M, McKinzie S, Busciglio I et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-81.
38. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.